EDSA - Company ID 0001540159
The table below shows Edesa Biotech, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.77M | $1.12M | $939.07K | $484.31K | $1.02M | $897.30K |
| SG&A |
Edesa Biotech, Inc. reported annual revenue of $0.00 for fiscal year 2021. That is down 100.0% from $328.80K in fiscal 2020. Over the 9 fiscal years shown, annual revenue declined from $286.05K (FY 2012) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.53M |
| $1.22M |
| $964.68K |
| $1.15M |
| $878.87K |
| $1.04M |
| Operating income | -$4.30M | -$2.34M | -$1.90M | -$1.64M | -$1.90M | -$1.93M |
| Income tax | $800.00 | - | $0.00 | $800.00 | - | $0.00 |
| Net income | -$4.22M | -$2.25M | -$1.75M | -$1.59M | -$1.62M | -$1.67M |
| EPS (diluted) | - | - | - | - | - | - |